Viva Biotech Holdings commences an Equity Buyback Plan for 193,503,680 shares, representing 10% of its issued share capital, under the authorization approved on June 30, 2023.

Viva Biotech Holdings (SEHK:1873) commences share repurchases on September 28, 2023, under the program mandated by the shareholders in the Annual General Meeting held on June 30, 2023. As per the mandate, the company is authorized to repurchase up to a maximum of 193,503,680 shares, representing 10% of the issued share capital. The purpose of the program is to enhance the net asset value per share and/or earnings per share.

The repurchases will be funded entirely from the cash flow or working capital facilities available to the Company and funds legally available for the purpose in accordance with the Articles of Association, applicable laws of the Cayman Islands and the Listing Rules. The authority shall expire at the earliest of the next Annual General Meeting, the date on which the next Annual General Meeting is required to be held or the date on which the authority is varied or revoked in a General Meeting. As of June 30, 2023, the company had 1,935,036,805 shares in issue.